(FHLC) Fidelity MSCI Health Care - Ratings and Ratios
Pharmaceuticals, Biotechnology, Medical Devices
Dividends
| Dividend Yield | 1.35% |
| Yield on Cost 5y | 1.97% |
| Yield CAGR 5y | 4.23% |
| Payout Consistency | 89.8% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 12.6% |
| Value at Risk 5%th | 20.8% |
| Relative Tail Risk | 0.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.44 |
| Alpha | 0.98 |
| CAGR/Max DD | 0.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.420 |
| Beta | 0.523 |
| Beta Downside | 0.549 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.87% |
| Mean DD | 5.43% |
| Median DD | 4.65% |
Description: FHLC Fidelity MSCI Health Care November 11, 2025
The Fidelity® MSCI Health Care Index ETF (FHLC) seeks to track the MSCI USA IMI Health Care 25/50 Index, allocating at least 80 % of its assets to the securities comprising that index. While it aims for broad coverage of U.S. health-care equities, the fund is classified as non-diversified because it may hold a concentrated subset of the index constituents.
Key quantitative points (as of the most recent filing) include an expense ratio of 0.08 %, a total net asset value of roughly $3 billion, and top holdings that typically feature large-cap pharma and biotech leaders such as Johnson & Johnson, UnitedHealth Group, and Pfizer, together representing about 30 % of the portfolio. The health-care sector has been driven in 2024 by an estimated 1.2 % annual growth in U.S. health-care spending, accelerated adoption of tele-medicine, and ongoing regulatory uncertainty around drug pricing reforms-factors that can materially affect the ETF’s performance.
For a deeper, data-rich analysis of FHLC’s risk-adjusted returns and sector exposure, you might explore the ValueRay platform, which aggregates real-time metrics and peer comparisons to help you evaluate whether this health-care play aligns with your investment thesis.
What is the price of FHLC shares?
Over the past week, the price has changed by +2.33%, over one month by +8.34%, over three months by +16.64% and over the past year by +9.75%.
Is FHLC a buy, sell or hold?
What are the forecasts/targets for the FHLC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 79.9 | 5.3% |
FHLC Fundamental Data Overview November 19, 2025
Beta = 0.74
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.76b USD (2.76b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.76b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.76b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.94% (E(2.76b)/V(2.76b) * Re(7.94%) + (debt-free company))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for FHLC ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle